Agni Casti, Agnocasto, Agnolyt, Agnus-Castus, Chaste Berry, Agneau du Moine, Agneau-chaste, Agni Casti, Agnocasto, Agnolyt, Agnus-Castus, Arbre au Poivre, Chaste Berry, Chaste Tree, Chaste Tree Berry, Chasteberry, Chastetree, Chinese Vitex, Gattilier, Hemp Tree, Herbe au Poivre, Mang Jing Zi, Monk's Pepper, Petit Poivre, Pimiento del Monje, Poivre de Moine, Poivre Sauvage, Vitex, Vitex Agnus Castus, Vitex rotundifolia, Vitex trifolia, Viticis Fructus.<br/><br/>


Overview Information

Vitex agnus-castus tree is a shrub that is native to the Mediterranean and Central Asia. The shrub has long, finger-shaped leaves, blue-violet flowers, and dark purple berries. The fruit and seed are used to make medicine.

Vitex agnus-castus is commonly taken by mouth for conditions related to the menstrual cycle such as premenstrual syndrome and a more severe form called premenstrual dysphoric disorder. It is also used for "lumpy" breasts and and many other conditions.

How does it work?

Vitex agnus-castus seems to affect many hormones that are involved in women's reproductive cycle.


Uses & Effectiveness?

Possibly Effective for

  • Premenstrual dysphoric disorder. Some research shows that vitex agnus-castus might work about as well as the prescription drug fluoxetine (Prozac) for relieving symptoms of this condition. Vitex agnus-castus seems to be better for physical symptoms like breast tenderness, swelling, and cramps. Fluoxetine seems to be better for depressed mood, feeling nervous and feeling out of control.
  • Premenstrual syndrome. Some research shows that taking vitex agnus-castus decreases some symptoms, especially breast pain or tenderness, depressed mood or moodiness, anger, and headache. But it does not seem to help for bloating.

Possibly Ineffective for

  • Bone fractures. Taking vitex agnus-castus extract does not seem to improve the healing of broken bones.

Insufficient Evidence for

  • Bleeding caused by an intrauterine device. Early research shows that taking vitex agnus-castus three times daily might reduce bleeding caused by an intrauterine device.
  • Infertility. The effects of vitex agnus-castus on fertility is not clear. Some early research shows that it does not improve the chance of becoming pregnant in women with infrequent menstrual bleeding, but it might help those who do not produce enough progesterone.
  • Repelling insects. Early research shows that vitex agnus-castus seed extract repels ticks and fleas for 6 hours, mosquitoes for 3 to 8 hours, and biting flies for 3 hours, when applied to the skin.
  • Breast pain. Early research shows that vitex agnus-castus) might relieve breast pain.
  • Acne.
  • Dementia.
  • Enlarged prostate.
  • Eye pain.
  • Increasing lactation.
  • Insomnia.
  • Menopausal symptoms.
  • Nervousness.
  • Prevention of miscarriage.
  • Swelling.
  • Other conditions.
More evidence is needed to rate the effectiveness of vitex agnus-castus for these uses.

Side Effects

Side Effects & Safety

Vitex agnus-castus fruit extract is LIKELY SAFE for most people when taken by mouth appropriately. Uncommon side effects include upset stomach, nausea, itching, rash, headaches, acne, trouble sleeping, and weight gain. Some women notice a change in menstrual flow when they start taking vitex agnus-castus. Vitex-agnus-castus seed extract is POSSIBLY SAFE when applied to the skin appropriately.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Using vitex agnus-castus during pregnancy or breast-feeding is POSSIBLY UNSAFE. The concern is that vitex agnus-castus can interfere with hormones. Don't use vitex agnus-castus if you are pregnant or breast-feeding.

Hormone-sensitive conditions such as endometriosis; uterine fibroids; or cancer of the breast, uterus, or ovaries: Vitex agnus-castus can affect hormones and might affect estrogen levels. Don't use vitex agnus-castus if you have a hormone-sensitive condition.

In vitro fertilization: Vitex agnus-castus can interfere with the effectiveness of in vitro fertilization. Don't use vitex agnus-castus if you are undergoing this procedure.

Parkinson's disease. Vitex agnus-castus contains chemicals that affect the brain. These chemicals affect the brain similarly to some medications used for Parkinson's disease. Therefore, vitex agnus-castus might affect therapy for Parkinson's disease.

Schizophrenia or other psychotic disorders. Vitex agnus-castus seems to affect a chemical in the brain called dopamine. Some medications for mental disorders help to decrease dopamine. Therefore, taking vitex agnus-castus might affect therapy for certain mental disorders.



Moderate Interaction

Be cautious with this combination

  • Birth control pills (Contraceptive drugs) interacts with VITEX AGNUS-CASTUS

    Vitex agnus-castus seems to change hormone levels in the body. Birth control pills contain hormones. Taking vitex agnus-castus along with birth control pills might decrease the effectiveness of birth control pills. If you take birth control pills along with vitex agnus-castus, use an additional form of birth control such as a condom.<br/><br/> Some birth control pills include ethinyl estradiol and levonorgestrel (Triphasil), ethinyl estradiol and norethindrone (Ortho-Novum 1/35, Ortho-Novum 7/7/7), and others.

  • Estrogens interacts with VITEX AGNUS-CASTUS

    Vitex agnus-castus seems to change hormone levels in the body. Taking vitex agnus-castus along with estrogen pills might decrease the effects of estrogen pills.<br/><br/> Some estrogen pills include conjugated equine estrogens (Premarin), ethinyl estradiol, estradiol, and others.

  • Medications for mental conditions (Antipsychotic drugs) interacts with VITEX AGNUS-CASTUS

    Vitex agnus-castus seems to affect a chemical in the brain called dopamine. Some medications for mental disorders help to decrease dopamine. Taking vitex agnus-castus along with medications for mental conditions might decrease the effectiveness of some medications for mental conditions.<br/><br/> Some medications for mental conditions include chlorpromazine (Thorazine), clozapine (Clozaril), fluphenazine (Prolixin), haloperidol (Haldol), olanzapine (Zyprexa), perphenazine (Trilafon), prochlorperazine (Compazine), quetiapine (Seroquel), risperidone (Risperdal), thioridazine (Mellaril), thiothixene (Navane), and others.

  • Medications used for Parkinson's disease (Dopamine agonists) interacts with VITEX AGNUS-CASTUS

    Vitex agnus-castus contains chemicals that affect the brain. These chemicals affect the brain similarly to some medications used for Parkinson's disease. Taking vitex agnus-castus with these medications might increase the effects and side effects of some medications used for Parkinson's disease.<br/><br/> Some medications used for Parkinson's disease include bromocriptine (Parlodel), levodopa (Dopar, component of Sinemet), pramipexole (Mirapex), ropinirole (Requip), and others.

  • Metoclopramide (Reglan) interacts with VITEX AGNUS-CASTUS

    Vitex agnus-castus seems to affect a certain brain chemical. This chemical is called dopamine. Metoclopramide (Reglan) also affects dopamine. Taking vitex agnus-castus along with metoclopramide might decrease the effectiveness of metoclopramide (Reglan).



The following doses have been studied in scientific research:


  • For premenstrual dysphoric disorder (PMDD): 20-40 mg of vitex agnus-castus extract taken daily for 8 weeks has been used.
  • For premenstrual syndrome (PMS): A specific extract known as BNO 1095 (Agnucaston/Cyclodynon, Bionorica AG), which contains 4 mg of vitex agnus-castus extract has been taken daily for three menstrual cycles. Another specific extract known as Ze 440 (Prefemin, Max Zeller Sohne AG, Romanshorn, Switzerland) which contains 20 mg of vitex agnus-castus extract has been taken daily for three menstrual cycles. Another specific product (Femicur, Schaper & Brummer GmbH & Co. KG, Salzgitter, Germany) containing 6.4-12 mg of vitex agnus-castus extract has been taken daily in two divided doses for three menstrual cycles. Specific capsules (Agnolyt, Madaus AG, Cologne, Germany) containing 3.5-4.2 mg of vitex agnus-castus extract has been taken daily on days 16-35 over three menstrual cycles. Vitex agnus-castus extract, 40 drops added to one glass of fruit juice once daily before breakfast starting 6 days prior to menstrual bleeding and lasting until menstrual bleeding occurs, has been used for six cycles.

View References


  • Glemain, C. Coulange F. N. Grapin et al. No benefit in combining tamsulosin with Serenoa repens versus tamsulosin alone on storage/filling and voiding lower urinary tract symptoms. J Urol, 2002;167 (suppl 4)(Abstract 1486):374.
  • Glemain, P., Coulange, C., Billebaud, T., Gattegno, B., Muszynski, R., and Loeb, G. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial]. Prog.Urol. 2002;12(3):395-403. View abstract.
  • Goepel, M., Dinh, L., Mitchell, A., Schafers, R. F., Rubben, H., and Michel, M. C. Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo? Prostate 2-15-2001;46(3):226-232. View abstract.
  • Greca P and Volip R. Experience with a new drug in the medical treatment of prostatic adenoma. Urologia 1985;52:532-535.
  • Groom, S. N., Johns, T., and Oldfield, P. R. The potency of immunomodulatory herbs may be primarily dependent upon macrophage activation. J Med Food 2007;10(1):73-79. View abstract.
  • Hanaka, M., Yoshii, C., Yatera, K., Ito, C., Chojin, Y., Nagata, S., Yamasaki, K., Nishida, C., Kawanami, T., Kawanami, Y., Ishimoto, H., and Mukae, H. [A case of rhabdomyolysis caused by saw palmetto of healthy foods]. J.UOEH. 6-1-2012;34(2):193-199. View abstract.
  • Hizli, F. and Uygur, M. C. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int.Urol.Nephrol. 2007;39(3):879-886. View abstract.
  • Hostanska, K., Suter, A., Melzer, J., and Saller, R. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res 2007;27(2):873-881. View abstract.
  • Hutchison, A., Farmer, R., Verhamme, K., Berges, R., and Navarrete, R. V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007;51(1):207-215. View abstract.
  • Iehle, C., Delos, S., Guirou, O., Tate, R., Raynaud, J. P., and Martin, P. M. Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54(5-6):273-279. View abstract.
  • Iguchi, K., Okumura, N., Usui, S., Sajiki, H., Hirota, K., and Hirano, K. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001;47(1):59-65. View abstract.
  • Ishii, K., Usui, S., Sugimura, Y., Yamamoto, H., Yoshikawa, K., and Hiran, K. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 2001;24(2):188-190. View abstract.
  • Kondas, J., Philipp, V., and Dioszeghy, G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol.Nephrol. 1996;28(6):767-772. View abstract.
  • Kul'chavenia, E. V., Breusov, A. A., Brizhatiuk, E. V., and Kholtobin, D. P. [Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections]. Urologiia. 2010;(6):55-58. View abstract.
  • Lapi, F., Gallo, E., Giocaliere, E., Vietri, M., Baronti, R., Pieraccini, G., Tafi, A., Menniti-Ippolito, F., Mugelli, A., Firenzuoli, F., and Vannacci, A. Acute liver damage due to Serenoa repens: a case report. Br.J.Clin.Pharmacol. 2010;69(5):558-560. View abstract.
  • Lobelenz J. [Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). klinische prufung im stadium I und II]. Therapeutikon. 1992;6(1-2):34-37.
  • Löbelenz J. Extractum Sabal fructus bei benigner Prostatahyperplasie (BPH): Klinische Prüfung im Stadium I und II. Therapeutikon 1992;6(1-2):34, 37.
  • Lopatkin, N. A., Sivkov, A. V., Medvedev, A. A., Walter, K., Schlefke, S., Avdeichuk, IuI, Golubev, G. V., Mel'nik, K. P., Elenberger, N. A., and Engelman, U. [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial]. Urologiia. 2006;(2):12, 14-12, 19. View abstract.
  • MacDonald, R., Tacklind, J. W., Rutks, I., and Wilt, T. J. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU.Int. 2012;109(12):1756-1761. View abstract.
  • MacLaughlin, B. W., Gutsmuths, B., Pretner, E., Jonas, W. B., Ives, J., Kulawardane, D. V., and Amri, H. Effects of homeopathic preparations on human prostate cancer growth in cellular and animal models. Integr.Cancer Ther 2006;5(4):362-372. View abstract.
  • Magri, V., Trinchieri, A., Montanari, E., Del Nero, A., Mangiarotti, B., Zirpoli, P., de Eguileor, M., Marras, E., Ceriani, I., Vral, A., and Perletti, G. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. Arch Ital Urol Androl 2007;79(2):84-92. View abstract.
  • Magri, V., Trinchieri, A., Pozzi, G., Restelli, A., Garlaschi, M. C., Torresani, E., Zirpoli, P., Marras, E., and Perletti, G. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob.Agents 2007;29(5):549-556. View abstract.
  • Mandressi A, Tarallo U, Maggioni A, and et al. Terapia medica dell'adenoma prostatico: confronto della efficacia del'estratto di serenoa repens (Permixon) versus l'estratto di pigeum africanum e placebo. Valutazione in doppio cieco. Urologia 1983;50(4):752-757.
  • Mandressi A. Treatment of uncomplicated benign prostatic hypertrophy (BPH) by an extract of Serenoa repens: clinical results. J Endocrinol Invest 1987;10 (suppl 2):49.
  • Mandressi S, Tarallo U Maggioni A Tombolini P Rocco F Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon) compared to that of the extract of Pygeum africanum and a placebo. Urologia. 1983;50(4):752-758.
  • Mantovani, F. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. Minerva Urol.Nefrol. 2010;62(4):335-340. View abstract.
  • Mattei FM, Capone M Acconcia A. [Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme]. TW Urologie Nephrologie. 1990;2:346-350.
  • Mattei FM, Capone M, and Acconcia A. Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme. TW Urol Nephrol 1990;2(5):346-350.
  • Medvedev, A. A., Siniakova, L. A., and Zaitsev, A. V. [Prostaplant treatment of benign prostatic hyperplasia]. Urologiia 2000;(4):13-15. View abstract.
  • Metzker H, Kieser M Holscher U. [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B. 1996;36(4):292-300.
  • Metzker H, Kieser M, and Hölscher U. Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH). Urologe 1996;36(4):292-300.
  • Miroddi, M., Carni, A., Mannucci, C., Moleti, M., Navarra, M., and Calapai, G. Hot flashes in a young girl: a wake-up call concerning Serenoa repens use in children. Pediatrics 2012;130(5):e1374-e1376. View abstract.
  • Mitropoulos D, Kiroudi A, Mitsogiannis I, and et al. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cells accumulation and glandular epithelium trophism in the rat prostate. J Urol 1999;161(4S):362.
  • Mohanty NK, Jha RJ, and Dutt C. Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic grade I to grade II benign prostatic hyperplasia (BPH). Indian J Urol 1999;16(1):26-31.
  • Morganti P, Fabrizi G, James B, and et al. Effect of gelatin-cystine and Serenoa repens extract on free radicals level and hair growth. J Appl Cosmetol 1998;16:57-64.
  • Morgia, G., Mucciardi, G., Gali, A., Madonia, M., Marchese, F., Di, Benedetto A., Romano, G., Bonvissuto, G., Castelli, T., Macchione, L., and Magno, C. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol.Int. 2010;84(4):400-406. View abstract.
  • Neff, K. D., Sandoval, H. P., Fernandez de Castro, L. E., Nowacki, A. S., Vroman, D. T., and Solomon, K. D. Factors associated with intraoperative floppy iris syndrome. Ophthalmology 2009;116(4):658-663. View abstract.
  • Pannunzio E, D'Ascenzo R, Giardinetti F, and et al. Serenoa repens vs. gestonorone caproato nel trattamento dell'ipertrofia prostatica benigna. Studio randomizzato. Urologia 1986;53(5):696-705.
  • Paoletti PP, Francalanci R, Tenti S, and et al. Medical treatment of prostatic hypertrophy. Experience with Serenoa repens extract. Urologia 1986;53:182-187.
  • Paubert-Braquet M, Raynaud JP, and Braquet PG. Permixon [lipid sterolic extract of
  • Paubert-Braquet, M., Cousse, H., Raynaud, J. P., Mencia-Huerta, J. M., and Braquet, P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33(3):340-347. View abstract.
  • Paubert-Braquet, M., Richardson, F. O., Servent-Saez, N., Gordon, W. C., Monge, M. C., Bazan, N. G., Authie, D., and Braquet, P. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone- induced experimental prostate enlargement in the rat. Pharmacol Res 1996;34(3-4):171-179. View abstract.
  • Pavone, C., Abbadessa, D., Tarantino, M. L., Oxenius, I., Lagana, A., Lupo, A., and Rinella, M. [Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients]. Urologia. 2010;77(1):43-51. View abstract.
  • Pecoraro, S., Annecchiarico, A., Gambardella, M. C., and Sepe, G. [Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate]. Minerva Urol.Nefrol. 2004;56(1):73-78. View abstract.
  • Plosker, G. L. and Brogden, R. N. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9(5):379-395. View abstract.
  • Pytel, Y. A., Vinarov, A., Lopatkin, N., Sivkov, A., Gorilovsky, L., and Raynaud, J. P. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv.Ther 2002;19(6):297-306. View abstract.
  • Redecker KD. [Sabal extract WS 1473 in benign prostatic hyperplasia]. Extracta Urologica 1998;21(3):23-25.
  • Reece Smith H, Memon A, Smart C, and et al. The value of Permixon in benign prostatic hypertrophy. Brit J Urol 1986;58(1):36-40.
  • Rhodes, L., Primka, R. L., Berman, C., Vergult, G., Gabriel, M., Pierre-Malice, M., and Gibelin, B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 1993;22(1):43-51. View abstract.
  • Roveda S and Colombo P. Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160mg or rectal capsules 640mg. Arch Med Interna 1994;46(2):61-75.
  • Savel'eva KV, Kachanova MV Pavlov VN Kazikhinurov RA Frolov MY Mukhin AB Udut VV Yurmazov ZA Dugina YL Sergeeva SA Epshtein OI. Clinical study of the efficiency and safety of afala in patients with benign prostatic hyperplasia. Bull Exp Biol Med. 2009;148(2):305-307.
  • Scaglione, F., Lucini, V., Pannacci, M., Dugnani, S., and Leone, C. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur.Rev.Med.Pharmacol.Sci. 2012;16(5):569-574. View abstract.
  • Schneider, H. J., Honold, E., and Masuhr, T. [Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices]. Fortschr Med 1-30-1995;113(3):37-40. View abstract.
  • Semino A, Ortega L, Cobo G, and et al. [Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens.]. Archivos Espanoles de Urologia 1992;45(3):211-213.
  • Shi, R., Xie, Q., Gang, X., Lun, J., Cheng, L., Pantuck, A., and Rao, J. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. J.Urol. 2008;179(2):610-615. View abstract.
  • Sinclair, R. D., Mallari, R. S., and Tate, B. Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. Australas.J Dermatol. 2002;43(4):311-312. View abstract.
  • Sokeland J and Albrecht J. Kombination aus Sabal und Urticaextrakt vs. finasterid bei BPH (Stad I bis II nach Alken). Urologe 1997;36 (4):327-333.
  • Sosnowska J, Balslev H. American palm ethnomedicine: a meta-analysis. J Ethnobiol Ethnomed. 2009;24(5):43.
  • Tasca, A., Barulli, M., Cavazzana, A., Zattoni, F., Artibani, W., and Pagano, F. [Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo]. Minerva Urol.Nefrol. 1985;37(1):87-91. View abstract.
  • Timmermans, L. M. and Timmermans, L. G., Jr. [Determination of the activity of extracts of Echinaceae and Sabal in the treatment of idiopathic megabladder in women]. Acta Urol Belg. 1990;58(2):43-59. View abstract.
  • Tosto A, Rovereto B, Paoletti MC, and et al. Study of Serenoa repens in treatment of functional secondary adenoma of the prostate: consideration of 20 cases. Urologia 1985;52:536-542.
  • Vacherot F, Azzouz M, Gil-Diez-De-Medina S, and et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSEr, Permixon) in benign prostatic hyperplasia. Prostate 2000;45(3):259-266.
  • Vahlensieck, W., Jr., Volp, A., Lubos, W., and Kuntze, M. [Benign prostatic hyperplasia--treatment with sabal fruit extract. A treatment study of 1,334 patients]. Fortschr Med 6-30-1993;111(18):323-326. View abstract.
  • Van Coppenolle F, Le Bourhis X, Carpentier F, and et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000;43(1):49-58.
  • Vela-Navarrete, R., Escribano-Burgos, M., Farre, A. L., Garcia-Cardoso, J., Manzarbeitia, F., and Carrasco, C. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol. 2005;173(2):507-510. View abstract.
  • Wargo, K. A., Allman, E., and Ibrahim, F. A possible case of saw palmetto-induced pancreatitis. South.Med.J. 2010;103(7):683-685. View abstract.
  • Webber, R. Benign prostatic hyperplasia. Clin Evid. 2005;(14):1076-1091. View abstract.
  • Weisser, H., Tunn, S., Behnke, B., and Krieg, M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 1996;28(5):300-306. View abstract.
  • Yeu, E. and Grostern, R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract.Surg 2007;33(5):927-928. View abstract.
  • Ziegler H and Holscher U. Efficacy of saw palmetto fruit special extract WS1473 in patients with Alken stage I-II benign prostatic hyperplasia--open multicentre study. Jatros Uro 1998;14(3):34-43.
  • Adriazola-Semino M, Lozano-Ortega JL, Garcia-Cobo E, et al. [Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens]. Arch Esp Urol 1992; 45:211-3. View abstract.
  • Argirovic A, Argirovic D. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? Vojnosanit Pregl 2013;70(12):1091-6. View abstract.
  • Avins AL, Bent S, Staccone S, et al. A detailed safety assessment of a saw palmetto extract. Complement Ther Med 2008;16:147-54. View abstract.
  • Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto on lower urinary tract symptoms: a randomized trial. JAMA 2011;306:1344-51. View abstract.
  • Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5 alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999;40:232-41. View abstract.
  • Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of serenoa repens (permixon&reg;) on the prostate. J Urol 2000;164:876-81. View abstract.
  • Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66. View abstract.
  • Bonnar-Pizzorno RM, Littman AJ, Kestin M, White E. Saw palmetto supplement use and prostate cancer risk. Nutr Cancer 2006;55:21-7. View abstract.
  • Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533-9. View abstract.
  • Braeckman J. The extract of serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 1994;55:776-85.
  • Busetto GM, Giovannone R, Ferro M,et al. Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®). BMC Urol. 2014;14:53. doi: 10.1186/1471-2490-14-53. View abstract.
  • Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 1990;66:639-41. View abstract.
  • Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-40. View abstract.
  • Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984;18:461-2. View abstract.
  • Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. J Intern Med 2001;250:167-9. View abstract.
  • Coulson S, Rao A, Beck SL, et al. A phase II randomized double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Compl Ther Med 2013;21:172-9. View abstract.
  • Debruyne F, Koch G, Boyle P, et al. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. Eur Urol 2002;41:497-506. View abstract.
  • Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders Clin Drug Invest 1995; 9:291-7.
  • Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-14. View abstract.
  • Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37:77-83. View abstract.
  • Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urol 1998;51:1003-7. View abstract.
  • Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000;163:1408-12. View abstract.
  • Glemain P, Coulange C, Grapin FN, Muszynski RC. No benefit in combining tamsulosin with Serenoa repens versus tamsulosin alone on storage/filling and voiding lower urinary tract symptoms. [Abstract]. J Urol 2001;167:374.
  • Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 1999;38:208-15. View abstract.
  • Goldmann WH, Sharma AL, Currier SJ, et al. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 2001;25:1117-24. View abstract.
  • Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995;48:97-103. View abstract.
  • Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76:428-40. . View abstract.
  • Gutierrez M, Garcia de Boto MJ, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol 1996;27:171-6. View abstract.
  • Habib FK, Ross M, Ho CK, et al. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 2005;114:190-4. View abstract.
  • Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004;7:195-200. View abstract.
  • Hamid S, Rojter S, Vierling J. Protracted cholestatic hepatitis after the use of Prostata. Ann Intern Med 1997;127:169-70. View abstract.
  • Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Saf 2005;28:319-32.. View abstract.
  • Dinç T, Coskun F. Comparison of fructus agni casti and flurbiprofen in the treatment of cyclic mastalgia in premenopausal women. Ulus Cerrahi Derg. 2014 Mar 1;30(1):34-8 View abstract.
  • Dixon-Shanies D, Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep 1999;6:1383-7.. View abstract.
  • Du Mee C. Vitex agnus castus. Aust J Med Herb 1993;5:63-5.
  • Eagon PK, Elm MS, Hunter DS, et al. Medicinal herbs: modulation of estrogen action. Era of Hope Mtg, Dept Defense; Breast Cancer Res Prog, Atlanta, GA 2000;Jun 8-11.
  • Eftekhari MH, Rostami ZH, Emami MJ, Tabatabaee HR. Effects of "vitex agnus castus" extract and magnesium supplementation, alone and in combination, on osteogenic and angiogenic factors and fracture healing in women with long bone fracture. J Res Med Sci. 2014 Jan;19(1):1-7. View abstract.
  • Gerhard II, Patek A, Monga B, et al. Mastodynon for female infertility. (abstract) Forsch Komplementarmed 1998;5:272-8. View abstract.
  • Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast 1999;8:175-81. View abstract.
  • Hossain MM, Paul N, Sohrab MH, et al. Antibacterial activity of Vitex trifolia. Fitoterapia 2001;72:695-7. View abstract.
  • Jarry H, Leonhardt S., Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus Castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994;102:448-54. View abstract.
  • Krapfl E. Prospektiv randomisierte klinische thrapiestudie zum wirksamkeitsvergleich von Orgametril&reg;, einem 19 nor-testosteron-derivat, versus Mastodynon&reg;, agnus castus-haltigen alkoholischen pflanzenextrakt, bei schmerzhafter mastopathie. Dissertation 1988;
  • Lauritzen CH, Reuter HD, Repges R, et al. Treatment of premenstrual tension syndrome with Vitex agnus castus: Controlled-double blind versus pyridoxine. Phytomedicine 1997;4:183-9.
  • Liu J, Burdette JE, Sun Y, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine 2004;11:18-23. View abstract.
  • Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001;49:2472-9.. View abstract.
  • Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med 2000;9:315-20. View abstract.
  • Mehlhorn H, Schmahl G, Schmidt J. Extract of the seeds of the plant Vitex agnus castus proven to be highly efficacious as a repellent against ticks, fleas, mosquitoes and biting flies. Parasitol Res 2005;95:363-5. View abstract.
  • Meier B, Berger D, Hoberg E, et al. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 2000;7:373-81. View abstract.
  • Merz P, Gorkow C, Schroder A, et al. The effects of a special Agnus castus extract (BP1095el) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes 1996;104:447-53. View abstract.
  • Milewicz A, Gejdel E, Sworen H, et al. [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study]. Arzneimittelforschung 1993;43:752-6.. View abstract.
  • Momoeda M, Sasaki H, Tagashira E, Ogishima M, Takano Y, Ochiai K. Efficacy and safety of Vitex agnus-castus extract for treatment of premenstrual syndrome in Japanese patients: a prospective, open-label study. Adv Ther. 2014 Mar;31(3):362-73. View abstract.
  • Ohyama K, Akaike T, Hirobe C, Yamakawa T. Cytotoxicity and apoptotic inducibility of Vitex agnus-castus fruit extract in cultured human normal and cancer cells and effect on growth. Biol Pharm Bull 2003;26:10-18. View abstract.
  • Okuyama E, Fujimori S, Yamazaki M, Deyama T. Pharmacologically active components of viticis fructus (Vitex rotundifolia). II. The components having analgesic effects. Chem Pharm Bull (Tokyo) 1998;46:655-62. View abstract.
  • Ono M, Yanaka T, Yamamoto M, et al. New diterpenes and norditerpenes from the fruits of Vitex rotundifolia. J Nat Prod 2002;65:537-41. View abstract.
  • Prilepskaya VN, Ledina AV, Tagiyeva AV, Revazova FS. Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome. Maturitas 2006;55 Suppl 1:S55-63.
  • Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007;23:117-22. View abstract.
  • Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo-controlled study. BMJ 2001;322:134-7. View abstract.
  • Shin TY, Kim SH, Lim JP, et al. Effect of Vitex rotundifolia on immediate-type allergic reaction. J Ethnopharmacol 2000;72:443-50. View abstract.
  • Turner S, Mills S. A double-blind clinical trial on a herbal remedy for premenstrual syndrome: a case study. Complement Ther Med 1993;1:73-77.
  • Upton R, ed. Chaste Tree Fruit. American Herbal Pharmacopoeia and Therapeutic Compendium. Santa Cruz, CA; American Herbal Pharmacopoeia 2001:1-37.
  • Van Die MD, Burger HC, Teede HG, Bone KM. Vitex agnus castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med 2013:79:562-575. View abstract.
  • Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)--pharmacology and clinical indications. Phytomedicine 2003;10:348-57. View abstract.
  • Wuttke W. Dopaminergic action of extracts of Agnus Castus. Forschende Komplementarmedizen 1996;3:329-30.
  • Yavarikia P, Shahnazi M, Hadavand Mirzaie S, Javadzadeh Y, Lutfi R. Comparing the effect of mefenamic Acid and vitex agnus on intrauterine device induced bleeding. J Caring Sci. 2013 Aug 31;2(3):245-54. View abstract.
  • Ben-Arye, E., Oren, A., and Ben-Arie, A. [Herbal medicine in womens' life cycle]. Harefuah 2006;145(10):738-42, 782. View abstract.
  • Bleier W. Therapie von Zyklus- und Blutungsstorungen und weiteren endokrin bedingten Erkrankungen der Frau mit pflanzlichen Wirkstoffen. Zbl Gynakol 1959;81:701-709.
  • Bubenzer RH. Therapy with Agnus castus extract (Strotan
  • Ciotta, L., Pagano, I., Stracquadanio, M., Di, Leo S., Ando, A., and Formuso, C. [Psychic aspects of the premenstrual dysphoric disorders. New therapeutic strategies: our experience with Vitex agnus castus]. Minerva Ginecol. 2011;63(3):237-245. View abstract.
  • Coeugniet E. Premenstrual syndrome and its treatment. Arztezeitchr Naturheilverf 1986;27:619-622.
  • Dante, G. and Facchinetti, F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom.Obstet.Gynaecol. 2011;32(1):42-51. View abstract.
  • Dennehy, C. E. The use of herbs and dietary supplements in gynecology: an evidence-based review. J Midwifery Womens Health 2006;51(6):402-409. View abstract.
  • Dittmar FW. Premenstrual syndrome: treatment with a phytopharmaceutical [in German]. TW Gynakologie 1992;5(1):60-68.
  • Doll, M. [The premenstrual syndrome: effectiveness of Vitex agnus castus]. Med.Monatsschr.Pharm. 2009;32(5):186-191. View abstract.
  • Dugoua, J. J., Seely, D., Perri, D., Koren, G., and Mills, E. Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation. Can.J Clin Pharmacol. 2008;15(1):e74-e79. View abstract.
  • Feldmann HU, Albrecht M, Lamertz M, and et al. The treatment of corpus Luteum insufficiency and premenstrual syndrome. Experience in a multicenter study under clinical practice conditions. [in German]. Gyne 1990;11(12):421-425.
  • Fersizoglou NE. Hormonale und thermographische veränderungen unter konservativer therapie der mastophathie. Vergleich von danazol, tamoxifen, lisurid, lynesterenol und einem phytopharmakon. Dissertation 1989;
  • Fikentscher, H. [Aetiology, diagnosis und therapy of mastopathy and mastodynia. Experiences of treatment with mastodynon (author's transl)]. Med Klin 8-26-1977;72(34):1327-1330. View abstract.
  • Fournier D and Grumbrecht C. Behandlung der mastopathie, mastodynie und des prämenstruellen syndroms. Verleich medikamentöser behandlung zu unbehandelten kontrollen. Therapiewoche 1987;37(5):430-434.
  • Freeman, E. W. Therapeutic management of premenstrual syndrome. Expert.Opin.Pharmacother. 2010;11(17):2879-2889. View abstract.
  • Fugh-Berman, A. and Kronenberg, F. Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod Toxicol. 2003;17(2):137-152. View abstract.
  • Göbel R. Results of the clinical evaluations of Danazol in benign breast disease compared with local treatment, gestagens, and bromocriptine. In: Baum M, George WD, and Hughes LE. Benign Breast Diseases. London: Roy Soc Med Int;1985.
  • Gregl A. Klinik und therapie der mastodynie. Med Welt 1985;36:242-246.
  • Halaska, M., Raus, K., Beles, P., Martan, A., and Paithner, K. G. [Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo]. Ceska.Gynekol. 1998;63(5):388-392. View abstract.
  • Halder R. Über die anwendungsmoglichkeiten von vitex agnus-castus L. in der frauenheilkunde unter besonderer berücksichtigung der blutungsstörungen. Dissertation 1957;
  • He, Z., Chen, R., Zhou, Y., Geng, L., Zhang, Z., Chen, S., Yao, Y., Lu, J., and Lin, S. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas 5-20-2009;63(1):99-103. View abstract.
  • Jarry H, Leonhardt S, Wuttke W, and et al. [Agnus castus as a dopaminergic active constituent in Mastodynon N]. Zeitschrift fur Phytotherapie 1991;12:77-82.
  • Jarry, H., Spengler, B., Porzel, A., Schmidt, J., Wuttke, W., and Christoffel, V. Evidence for Estrogen Receptor beta-Selective Activity of Vitex agnus-castus and Isolated Flavones. Planta Med 2003;69(10):945-947. View abstract.
  • Kayser HW and Istanbulluoglu S. Vitex agnus castus. Hippokrates 1954;25:717-719.
  • Kubista, E., Muller, G., and Spona, J. [Treatment of mastopathies with cyclic mastodynia. Clinical results and hormonal profiles]. Rev Fr.Gynecol Obstet 1987;82(4):221-227. View abstract.
  • Laakmann, E., Grajecki, D., Doege, K., zu, Eulenburg C., and Buhling, K. J. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol.Endocrinol. 2012;28(9):703-709. View abstract.
  • Lauritzen, C., Reuter, H. D., Repges, R., Bohnert, K. J., and Schmidt, U. Treatment of premenstrual tension syndrome with Vitex agnus castus controlled, double-blind study versus pyridoxine. Phytomedicine. 1997;4(3):183-189. View abstract.
  • Liebel H. Behandlung des prämenstruellen Syndromes. Agnus castus-haltige Kombinationsarzneimittel im Test. Therapiewoche Gynakol 1992;5:2-12.
  • Lucks, B. C., Sorensen, J., and Veal, L. Vitexagnus-castus essential oil and menopausal balance: a self-care survey. Complement Ther Nurs.Midwifery 2002;8(3):148-154. View abstract.
  • Ma, L., Lin, S., Chen, R., and Wang, X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol.Endocrinol. 2010;26(8):612-616. View abstract.
  • Ma, L., Lin, S., Chen, R., Zhang, Y., Chen, F., and Wang, X. Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust.N.Z.J Obstet.Gynaecol. 2010;50(2):189-193. View abstract.

Vitamins Survey

Have you ever purchased VITEX AGNUS-CASTUS?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

More Resources for VITEX AGNUS-CASTUS

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.